VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IMCCIM Cannabis Corp.
$0.14$438442
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIMCCFinancials

IM Cannabis Corp. (IMCC) Financials

23Y historyFree accessUpdated daily

Revenue plummeted to $6.3 million in 2026Q1, while gross margins compressed to 16.3%, reflecting significant challenges in managing landed costs for premium flower.

IMCC Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Apr'18Apr'17Apr'16Apr'15Apr'14Apr'13Apr'12Apr'11Apr'10Apr'09Apr'08Apr'07Apr'06Apr'05Apr'04
Sales/Revenue44.12M54.73M54.03M48.8M54.34M34.05M15.89M9.07M5.2M4.39M00000000000000
Revenue Growth %-18.99%1.3%10.71%-10.18%59.56%114.3%75.12%74.6%18.3%---------------
Cost of Goods Sold36.87M45.05M45.58M38.96M45.17M27.72M5.42M5.14M999K1.59M05145.61K00000000000
COGS % of Revenue-82.3%84.36%79.83%83.14%81.4%34.12%56.7%19.22%36.19%--------------
Gross Profit7.25M9.69M8.45M9.85M9.16M6.33M10.47M3.93M4.2M2.8M0-514-5.61K00000000000
Gross Margin %16.43%17.7%15.64%20.17%16.86%18.6%65.88%43.3%80.78%63.81%--------------
Gross Profit Growth %-14.61%-14.17%7.47%44.67%-39.5%166.43%-6.41%49.77%-100%90.84%------------
Operating Expenses15.79M21.27M18.68M22.64M39.95M29.37M18.71M14.2M2.74M1.81M15.25K44.47K221.17K218.96K302.5K522.29K675.73K1.32M1.55M367.12K351.13K350.49K424.86K409.32K
OpEx % of Revenue-38.87%34.58%46.39%73.53%86.24%117.77%156.54%52.8%41.18%--------------
Selling, General & Admin12.74M12.94M13.28M19.03M28.91M28.09M18.71M10.34M3.03M124.91K15.25K43.96K221.17K213.99K288.9K506.38K655.07K1.31M1.4M356.9K348.85K347.96K420.9K405.36K
SG&A % of Revenue-23.64%24.58%39%53.2%82.5%117.77%113.94%58.3%2.84%--------------
Research & Development000000136K233K83K000001.12K1.36K3.64K0139.43K00000
R&D % of Revenue------0.86%2.57%1.6%---------------
Other Operating Expenses975.34K8.34M5.41M3.61M11.05M1.27M-136K3.63M-369K1.68M051404.97K12.48K14.56K17.02K12.61K14.57K10.22K2.29K2.52K3.96K3.96K
Operating Income-8.54M-11.59M-10.23M-12.79M-30.79M-23.04M-8.24M-10.28M3.08M-125K-15.25K-44.47K-227K-218.96K-303K-522.29K-675.73K-1.32M-1.55M-367K-543K-777K-424.86K-991K
Operating Margin %-19.36%-21.17%-18.94%-26.21%-56.67%-67.64%-51.89%-113.24%59.32%-2.85%--------------
Operating Income Growth %--13.22%20%58.46%-33.67%-179.38%19.76%-433.28%2566.4%-719.67%65.71%80.41%-3.67%27.74%41.99%22.71%48.82%14.77%-322.07%32.41%30.12%-82.88%57.13%-
EBITDA-6.92M-9.63M-8.05M-9.8M-23.46M-17.31M-7.32M-9.67M3.26M-44K7.57K-43.96K-221.39K-208.8K-283.12K-507.73K-658.71K-1.31M-1.53M-356.78K-540.71K-774.48K-420.9K-987.04K
EBITDA Margin %-15.68%-17.6%-14.9%-20.07%-43.18%-50.82%-46.04%-106.61%62.79%-1%--------------
EBITDA Growth %49.79%-19.64%17.82%58.24%-35.56%-136.58%24.38%-396.48%7515.91%-681.55%117.21%80.15%-6.03%26.25%44.24%22.92%49.62%14.78%-330.05%34.02%30.18%-84.01%57.36%-
D&A (Non-Cash Add-back)1.63M1.96M2.18M3M7.33M5.73M930K601K180K81K22.82K5145.61K10.16K19.88K14.56K17.02K12.61K14.65K10.22K2.29K2.52K3.96K3.96K
EBIT-6.66M-8.9M-8.33M-5.79M-24.09M509K-7.97M-6.62M3.08M-125K-15.25K-45.11K-79.61K-241.1K-10.04M-519.77K-669.18K-1.32M-1.41M-762K-611K-347K-376.43K-402K
Net Interest Income-608.28K-2.76M-2.56M3.33M4.73M22.87M-20.23M2.95M-84K26K00000000000000
Interest Income2.87M01.91M7.01M6.7M23.54M277K3.65M84K26K00000003.05K000000
Interest Expense3.48M2.76M4.47M3.67M1.97M673K20.5M707K0050050044122.13K19.48M1.73K7.04K3.05K16.64K384.28K267.99K913.05K-419.65K1.11M
Other Income/Expense-2.87M-71K-2.56M3.33M4.73M22.87M-20.23M2.95M285K-26K-500-1.14K146.74K-22.13K-9.74M-9416.54K-3.96K118.26K-384K-258K-59.11K419.65K53.52K
Pretax Income-11.41M-11.66M-12.79M-9.46M-26.06M-164K-28.47M-7.33M3.37M-125K-15.75K-45.61K-80.05K-241.09K-10.04M-523.23K0-1.33M-1.43M-751K-811K-837K-5.21K-938K
Pretax Margin %-25.86%-21.3%-23.68%-19.38%-47.96%-0.48%-179.18%-80.77%64.81%-2.85%--------------
Income Tax89.41K92K-1.02M771K-1.14M500K262K90K741K241K000014.81M-4.25K-13.59K906-152K395.28K452.15K913.05K0-273K
Effective Tax Rate %-0.78%-0.79%8%-8.15%4.37%-304.88%-0.92%-1.23%22%-192.8%0%0%0%0%-147.48%0.81%--0.07%10.62%-52.63%-55.75%-109.09%0%29.1%
Net Income-11.09M-11.32M-10.59M-9.5M-188.89M-17.76M-28.7M-7.29M1.68M538K-15.75K-45.61K-37.69K-228.34K-5.37M-519.77K-669.18K-1.32M-1.41M-762K-611K-837K-5.21K-666K
Net Margin %-25.15%-20.68%-19.59%-19.46%-347.64%-52.16%-180.6%-80.36%32.38%12.25%--------------
Net Income Growth %-136.72%-6.93%-11.44%94.97%-963.39%38.1%-293.55%-533.27%212.83%3515.87%65.47%-21.03%83.5%95.75%-933.91%22.33%49.46%6.36%-85.56%-24.71%27%-15952.93%99.22%-
Net Income (Continuing)-11.5M-11.75M-11.77M-10.23M-24.92M-664K-28.73M-7.42M2.63M0-15.75K-45.61K-80.05K-241.09K0-519.77K0-1.32M-1.41M-762K-611K0-5.21K-666K
Discontinued Operations0000-166.38M0000000000000000000
Minority Interest-72.95K-2.76M-2.1M-769K1.15M3.71M1.51M1.45M1.43M-11.81M-11.81M-11.81M-11.81M-3.51M-3.5M775.25K775.25K0000000
EPS (Diluted)-1.87-2.67-4.51-4.45-161.88-3.00-7.45-13.800.60-2.32-0.30-0.88-0.73-4.68-124.24-12.26-16.37-38.89-50.53-38.74-41.77-72.61-0.53-76.31
EPS Growth %-18.02%40.8%-1.35%97.25%-5296%59.73%46.01%-2400%125.86%-673.33%65.91%-20.55%84.4%96.23%-913.38%25.11%57.91%23.04%-30.43%7.25%42.47%-13600%99.31%-
EPS (Basic)--2.67-4.51-4.45-76.80-5.71-7.45-2.280.60-2.32-0.30-0.88-0.73-4.68-124.24-12.26-16.37-38.89-50.53-38.74-41.77-72.61-0.53-76.31
Diluted Shares Outstanding5.93M4.24M2.35M2.14M1.15M5.92M3.86M3.72M2.82M53.98K51.65K51.65K51.65K48.76K43.25K42.39K40.87K34.05K27.99K19.68K14.64K11.52K9.82K8.73K
Basic Shares Outstanding5.93M4.24M2.35M2.14M2.46M3.11M3.86M3.2M2.82M53.98K51.65K51.65K51.65K48.76K43.25K42.39K40.87K34.05K27.99K19.68K14.64K11.52K9.82K8.73K
Dividend Payout Ratio------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and Regulatory Exposure

Revenue Contraction Amid Strategic Pivot

As reported in recent financial filings, IMCC's revenue experienced a sharp decline to $6.3 million in 2026Q1, representing a 49.4% year-over-year contraction that underscores the volatility inherent in the company's transition away from Canadian operations toward a concentrated focus on the Israeli and German medical markets.

The significant drop in top-line performance suggests that the company's strategic pivot has yet to stabilize its revenue base. Investors should monitor whether this contraction reflects a permanent loss of market share or merely the expected outcome of exiting lower-margin recreational segments.

Structural Margin Compression Remains Persistent

Based on the company's latest income statement, gross margins have struggled to maintain consistency, fluctuating from a peak of 27.6% in 2025Q1 down to 16.3% in 2026Q1, which highlights the difficulty of managing high landed costs for imported premium flower in a competitive retail environment.

The inability to sustain gross margins above 20% suggests that the company lacks significant pricing power in its primary markets. This margin profile appears highly sensitive to the cost of third-party supply and logistics, which may continue to pressure profitability until a more efficient procurement model is established.

Operating Leverage Constrained by Overhead

According to historical income statement data, IMCC has failed to achieve meaningful operating leverage, as SG&A expenses frequently outpace gross profit, resulting in an operating margin of -19.3% in 2026Q1 that indicates an inability to scale the business model efficiently relative to its current revenue base.

The persistent gap between gross profit and operating expenses suggests that the company's fixed cost structure remains too heavy for its current scale. Without a substantial increase in revenue or a drastic reduction in overhead, the company may continue to face significant challenges in achieving operational break-even.

Sustainability Risks and Liquidity Concerns

Financial statements indicate that with a net loss of $1.7 million in 2026Q1 and limited cash reserves, the company faces a precarious liquidity position that may necessitate further dilutive financing or asset divestitures to sustain operations, as evidenced by the ongoing trend of negative net margins.

Short-term survival appears to be the primary concern, as the current burn rate relative to cash on hand leaves little room for operational error. Investors should remain cautious regarding the company's ability to navigate potential supply chain disruptions or further regulatory headwinds in its core Israeli market.

IMCC — Frequently Asked Questions

Quick answers to the most common questions about buying IMCC stock.

What was IM Cannabis Corp.'s (IMCC) revenue in 2025?

For fiscal year 2025, IM Cannabis Corp. (IMCC) reported total revenue of $54.7M.

Is IM Cannabis Corp. (IMCC) profitable?

IM Cannabis Corp. (IMCC) reported a net loss of $11.3M for the fiscal year ending 2025.

What is IM Cannabis Corp.'s operating profit margin?

IM Cannabis Corp. (IMCC) reported an operating income of $-11.6M, resulting in an operating profit margin of -21.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is IM Cannabis Corp.'s gross profit and gross margin?

IM Cannabis Corp. (IMCC) generated $9.7M in gross profit for the year, representing a gross profit margin of 17.7%. This demonstrates the company's core pricing power and production efficiency.